Trial Profile
A Randomized Open-Label, Single-Dose, Crossover Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Filgrastim Hospira Compared To U.S.-Approved Neupogen (Amgen) Following Subcutaneous Administration To Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Febrile neutropenia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Mar 2019 Results from two separate open-label, crossover-design PK/PD studies (NCT02766647 and NCT02766634) published in the BioDrugs
- 12 May 2016 New trial record